Company news
Marker Therapeutics, Inc. news in 2023
Marker Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
December 20, 2023
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
December 10, 2023
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
September 10, 2023
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 29, 2023
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
August 16, 2023
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 13, 2023
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
August 6, 2023
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
July 25, 2023
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
July 9, 2023
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
June 25, 2023
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
June 11, 2023
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
May 30, 2023
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
May 7, 2023
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
April 30, 2023
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
March 21, 2023